Literature DB >> 16403955

Clinical application of rapid assay of interleukin-6 in influenza-associated encephalopathy.

Mikage Nakamura1, Gaku Yamanaka, Hisashi Kawashima, Yoshiaki Watanabe, Hiroaki Ioi, Yasuyo Kashiwagi, Kouji Takekuma, Akinori Hoshika, Mizuho Hayakawa, Shigeru Suzuki.   

Abstract

The characteristics of influenza-associated encephalopathy is the high mortality and nimble progress with coma which appears in general cases within 48 hours. Most of patients show no abnormalities in the standard blood checks on admission or in early stage. In this study we investigated if a rapid assay of interleukin (IL)-6 is useful in influenza-associated encephalopathy in early stages. The levels of IL-6 in patients with influenza-associated encephalopathy did not show any significant difference compared with those in patients with febrile convulsion and rotavirus-associated convulsion. However the levels of IL-6 in severe cases were significantly higher than those of mild cases with influenza-associated encephalopathy. Consequently the rapid assay of serum IL-6 is useful to evaluate and decide the therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16403955      PMCID: PMC3851426          DOI: 10.1155/2005/671609

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  2 in total

1.  Encephalopathy Associated with Influenza B in a Healthy Young Man.

Authors:  Masaki Shimamoto; Satoshi Okada; Takeshi Terashima
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

2.  Abrogated Caveolin-1 expression via histone modification enzyme Setdb2 regulates brain edema in a mouse model of influenza-associated encephalopathy.

Authors:  Natsuko Imakita; Masahiro Kitabatake; Noriko Ouji-Sageshima; Atsushi Hara; Shoko Morita-Takemura; Kei Kasahara; Akihiro Matsukawa; Akio Wanaka; Keiichi Mikasa; Toshihiro Ito
Journal:  Sci Rep       Date:  2019-01-22       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.